Category Archives: Stem Cell Research

DUBLIN--(BUSINESS WIRE)--The "Global Cell Therapy Market, By Use Type, By Therapy Type, By Product, By Technology & By Region- Forecast and Analysis 2022-2028" report has been added to ResearchAndMarkets.com's offering.

The Global Cell Therapy Market was valued at USD 14.86 Billion in 2021, and it is expected to reach a value of USD 35.95 Billion by 2028, at a CAGR of 13.45% over the forecast period (2022 - 2028).

Companies Mentioned

The cell therapy industry is being propelled forward by an increase in the number of clinical trials for cell-based treatments. As a result, global investment in research and clinical translation has increased significantly. The increasing number of ongoing clinical studies can be attributed to the presence of government and commercial funding bodies that are constantly providing funds to assist projects at various stages of clinical trials.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cell Therapy Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research and their market shares in the respective regions were determined through primary and secondary research.

This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives.

All percentage shares split, and breakdowns were determined by using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Segments covered in this report

The global cell therapy market is segmented based on Use-type, Therapy Type, Product, Technology, Application, and Region. Based on Use-type it is categorized into Clinical-use, and Research-use. Based on Therapy Type it is categorized into Allogenic Therapies, Autologous Therapies.

Based on Product it is categorized into Consumables, Equipment, Systems, and Software. Based on Technology it is categorized into Viral Vector Technology, Genome Editing Technology, Somatic Cell Technology, Cell Immortalization Technology, Cell Plasticity Technology, and Three-Dimensional Technology. Based on the region it is categorized into North America, Europe, Asia-Pacific, South America, and MEA.

Drivers

The increased demand for novel, better medicines for diseases such as cancer and CVD has resulted in an increase in general research efforts as well as funding for cell-based research. In November 2019, the Australian government released The Stem Cell Therapies Mission, a 10-year strategy for stem cell research in Australia.

The project would receive a USD 102 million (AU$150 million) grant from the Medical Research Future Fund (MRFF) to encourage stem cell research in order to develop novel medicines. Similarly, the UK's innovation agency, Innovate the UK, awarded USD 269,670 (GBP 267,000) in funding in September 2019 to Atelerix's gel stabilization technologies, with the first goal of extending the shelf-life of Rexgenero's cell-based therapies for storage and transport at room temperature.

Restraints

Despite technological advancements and product development over the last decade, the industry has been hampered by a lack of skilled personnel to operate complex devices like flow cytometers and multi-mode readers. Flow cytometers and spectrophotometers, which are both technologically advanced and extremely complex, generate a wide range of data outputs that require skill to analyze and review.

There is a global demand-supply mismatch for competent individuals, according to the National Accrediting Agency for Clinical Laboratory Sciences (NAACLS). Over the next decade, the UK and Europe are expected to face a severe shortage of lab capabilities, with medical laboratories being particularly hard hit.

Market Trends

The expansion of the cell therapy market was aided by the growing frequency of chronic illnesses. Chronic illness is defined as a condition that lasts one year or more and requires medical treatment, affects everyday activities, or both, according to the US Centers for Disease Control and Prevention (CDC).

It includes heart disease, cancer, diabetes, and Parkinson's disease. Patients with spinal cord injuries, type 1 diabetes, Parkinson's disease (PD), heart disease, cancer, and osteoarthritis may benefit from stem cells.

For more information about this report visit https://www.researchandmarkets.com/r/aqmxta

More:
Global Cell Therapy Market Report (2022 to 2028) - Featuring Thermo Fisher Scientific, MaxCyte, Danaher and Avantor Among Others -...

When I was young,,,

36 reasons to VOTE YES! For Your Scientist Friends

By Don C. Reed

Author, STEM CELL BATTLES, other books

http://www.stemcellbattles.com

Dear Friend of Regenerative Medicine:

For the next month, I will make available a daily summary of one aspect of stem cell researchmy laymans understanding of itdone by scientists connected to the California Institute for Regenerative Medicine (CIRM). Todays is spina bifida, tomorrow is stroke.

Mistakes are mine.

In most cases I have left out the scientists names. A few I have written about in my books, and those I felt free to credit.

All I ask is that when you step into the voting booth, please consider which political party is likely to fund such research, and vote accordingly.

Spina Bifida: total awards (3) Award value: $16,798,263

The condition is devastating, and lasts a lifetime. The baby has a part of its spine bulging out of its lower back. Accompanying symptoms are many, including: headaches, vomiting, weakness in the legs, bladder and bowel problems.

Current standard of care (in utero surgery) leaves 58% of patients unable to walk independently.

39% of affected population are Hispanic or Latino descent.

The condition may cost several million dollars per patient, over his or her lifetime.

Spina Bifida (SB) appears to be caused by a combination of genetic and environmental conditions, but no one is sure. How will CIRM fight such a thing?

One way is Placenta-derived mesenchymal stem cells, seeded on a Cook Biodesign extracellular Matrix. Think of a mesh screen, over the wound.

THERAPEUTIC MECHANISM: Mesenchymal stem cellssecrete growth factors (and) cytokinesprotecting motor neurons from cell deathtreatment increases the density of motor neurons in the spinal cord, leading to improved motor functionultimately reducing lower limb paralysis. (1)

Grant recipient Diana Farmer began science as a marine biologist, who doing research at the famous Woods Hole Institute. On the way to receive an award, she suffered a car accident, and changed her mind, working on human biology. She was the first woman to perform surgery on a baby in its mothers womb. (1)

She and Aijun Wang received a CIRM grant to co-launch the worlds first human clinical trial using stem cells to treat spina bifida.. (2)

1. https://en.wikipedia.org/wiki/Diana_L._Farmer

2. https://health.ucdavis.edu/health-news/newsroom/state-stem-cell-agency-funds-clinical-trial-for-spina-bifida-treatment/2020/11

More:
Fighting One Disease or Condition per Day - Daily Kos

Not all stem cell transplants in individuals living with HIV and cancer, such as those used to cure Timothy Ray Brown and Adam Castillejo, among others, have been successful. Yet much can be learned about curing HIV from those whose lives could not be saved.

Research questionCurrently the only curative intervention for HIV is to transplant donor cells with a CCR5 delta32 genetic mutation in a person living with HIV (PLWH). But the impact of such transplants on HIV reservoirs in various organs has not been extensively characterized. A consortium of European researchers known as IciStem, established through amfAR funding, sought to gauge this impact by studying autopsy specimens from two individuals who underwent such transplants but were not cured and died soon afterwards.

FindingsThe first individual had been infected with HIV for 14 years and treated with antiretroviral therapy (ART) for that entire period. He was given a transplant in an attempt to cure a blood disorder known as MDS. On the 36th day following that procedure he achieved 100% chimerism. That meant that all his newly formed immune and other blood cells were the offspring of the donor and should be resistant to HIV infection. However, 29 days later that 100% value fell to 85%presumably related to an initially undetected population of recipient cells that were not destroyed by the transplant preparation procedure. He died of severe sepsis. At that time his blood still had no evidence of HIV, but all organs sampled, from brain to lymph node, showed signs of persistent infection.

The second individual had been infected with HIV for 22 years and treated with ART for the last 19 years. He required two transplants in an attempt to cure his acute leukemiathe first one having failed to take holdand on the 100th day following the first transplant (29 days after the second procedure) he achieved 100% chimerism. However, he died of lung failure eight days later. At that time no virus could be found in the blood, but the lymph node and spleen showed persistence of an HIV reservoir.

ImpactThe authors emphasize the need for examining tissues, not just blood, of PLWH having undergone potentially curative interventions as their results document that [t]issues play an essential role as a long-standing viral reservoir and routine [blood] sampling in living HIV-1-individuals will be insufficient to represent the extent of this reservoir.

amfARs roleamfAR was a funder of this research.

Original articlehttp://www.ncbi.nlm.nih.gov/pubmed/36146874

Dr. Laurence is amfARs senior scientific consultant.

See the article here:
The Issue of Tissue: Getting to the Source of the HIV Reservoir - amfAR, The Foundation for AIDS Research

DUBLIN--(BUSINESS WIRE)--The "Cell Isolation Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.

The global cell isolation market size reached US$ 10.3 Billion in 2021. Looking forward, the publisher expects the market to reach US$ 24.6 Billion by 2027, exhibiting a CAGR of 15.62% during 2021-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.

Cell isolation, or separation, refers to the process of identifying and removing one or more specific cells from a heterogeneous mixture of cell population. The targeted cells are identified, isolated and separated according to their type. Some commonly used methods for cell isolation include magnet-activated cell separation, filtration, centrifugation and flow cytometry.

Cell isolation is also used to diagnose diseases, cellular research and therapies by analyzing the ribonucleic acid (RNA) expressions. It aids in minimizing experimental complexity while analyzing the cells and reducing the interference from other cell types within the sample. As a result, it finds extensive application in cancer research, stem cell biology, immunology and neurology.

Cell Isolation Market Trends:

Significant growth in the medical and pharmaceutical industries is one of the key factors creating a positive outlook for the market. Furthermore, increasing emphasis on cell-based research is providing a thrust to the market growth. Researchers actively utilize isolated cells to develop novel cell therapies and cell-based treatments for various chronic medical ailments. Pharmaceutical manufacturers are also widely using cell isolation technologies to improve drug discovery and develop drugs with enhanced efficacies. In line with this, the increasing requirement for personalized medicines is also contributing to the growth of the market.

Additionally, the development of advanced separation tools for proteins, nucleic acids, chromatin and other complex cells for subsequent analysis is also contributing to the growth of the market. Other factors, including extensive research and development (R&D) activities in the field of biotechnology, along with the implementation of favorable government policies, are anticipated to drive the market toward growth.

Key Market Segmentation

Breakup by Technique:

Breakup by Cell Type:

Breakup by Product:

Breakup by Application:

Breakup by End Use:

Breakup by Region:

Key Questions Answered in This Report:

Key Topics Covered:

1 Preface

2 Scope and Methodology

3 Executive Summary

4 Introduction

5 Global Cell Isolation Market

6 Market Breakup by Technique

7 Market Breakup by Cell Type

8 Market Breakup by Product

9 Market Breakup by Application

10 Market Breakup by End Use

11 Market Breakup by Region

12 SWOT Analysis

13 Value Chain Analysis

14 Porters Five Forces Analysis

15 Price Analysis

16 Competitive Landscape

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/8hx8ne

More here:
Cell Isolation Global Market Report 2022: Significant Growth in the Medical and Pharmaceutical Industries Driving Sector - ResearchAndMarkets.com -...

Oct. 3, 2022, Irvine, Calif. UCI Health is pleased to announce a $2 million gift that will benefit the emergency department in the new $1.3 billion UCI Health Irvine medical campus being built on the corner of Jamboree Road and Birch Street in Irvine.

The gift, funded by the Nancy and Geoffrey Stack Family Foundation, will name the patient welcome areas in the emergency department of the planned acute care hospital and at the Chao Family Comprehensive Cancer Care and Ambulatory Care building.

UCI Health is grateful for the friendship and generosity of Nancy and Geoffrey Stack, said UCI Health CEO Chad Lefteris. With their support, we continue to improve access to the clinical innovation, lifesaving research, and world class care of Orange Countys only academic health system.

In November, UCI and the universitys health enterprise, UCI Health, officially broke ground on the medical complex, which will include a 144-bed general acute care hospital with an emergency department, the Chao Family Comprehensive Cancer Center and Ambulatory Care center and the Joe C. Wen & Family Center for Advanced Care.

The UCI Health Irvine complex will support the systems growing primary and specialty care network in coastal and south Orange County, Lefteris said.

UCI Health is a beacon of hope in Orange County, said Nancy Stack. The new medical complex will bring hope and healing to our region and will save lives. Jeff and I are honored to support such a worthwhile cause.

The Stacks are longtime supporters of UCI Health. The couple has made previous philanthropic gifts to support UCI Medical Center in Orange. They have continued their legacy of giving by investing in healthcare through the UCI Health Irvine medical campus.

The new UCI Health Irvine medical campus will complement the UCI Medical Center in Orange and will be a key part to providing the region with the advanced care available only from a health system that is part of a leading, premier academic research institution. The hospital will include a 24-hour emergency department and focus on leading clinical programs including oncology, neurology, neurosurgery, orthopedics, and digestive health. The first patients are expected in 2023 at the Joe. C. Wen & Family Center for Advanced Care. The Chao Family Comprehensive Cancer Care and Ambulatory Care building, and the hospital will begin serving patients in 2023 and 2025, respectively.

Nancy and Geoffrey Stack Family Foundation was created by the longtime Orange County residents to support education, health and other vital community-based programs in Orange County and beyond. Geoffrey Stack is one of the founding partners of the Sares-Regis Group, a commercial and residential real estate development and management firm. Nancy Stack is founder and president of the Cystinosis Research Foundation, which supports medical research including stem cell research seeking a cure for the rare disease cystinosis.

If you want to learn more about supporting this or other activities at UCI, please visit the Brilliant Future website athttps://brilliantfuture.uci.edu. Publicly launched on Oct. 4, 2019, the Brilliant Future campaign aims to raise awareness and support for UCI. By engaging 75,000 alumni and garnering $2 billion in philanthropic investment, UCI seeks to reach new heights of excellence instudent success,health and wellness, research and more. UCI Health plays a vital role in the success of the campaign. Learn more by visiting https://brilliantfuture.uci.edu/uci-health/

About UCI Health:UCI Healthis the clinical enterprise of the University of California, Irvine. Patients can access UCI Health at primary and specialty care offices across Orange County and at its main campus,UCI Medical Center in Orange, Calif. The 459-bed acute-care hospital, listed among Americas Best Hospitals byU.S. News & World Reportfor 22 consecutive years, provides tertiary and quaternary care, ambulatory and specialty medical clinics, as well as behavioral health and rehabilitation services. UCI Medical Center is home to Orange Countys onlyNational Cancer Institute-designated comprehensive cancer center,high-risk perinatal/neonatal programandAmerican College of Surgeons-verified Level I adult and Level II pediatric trauma centerandregional burn center. It is the primary teaching hospital for theUCI School of Medicine. UCI Health serves a region of nearly 4 million people in Orange County, western Riverside County and southeast Los Angeles County. Follow us onFacebookandTwitter.

About the University of California, Irvine:Founded in 1965, UCI is the youngest member of the prestigious Association of American Universities and is ranked among the nations top 10 public universities byU.S. News & World Report. The campus has produced three Nobel laureates and is known for its academic achievement, premier research, innovation and anteater mascot. Led by Chancellor Howard Gillman, UCI has more than 36,000 students and offers 224 degree programs. Its located in one of the worlds safest and most economically vibrant communities and is Orange Countys second-largest employer, contributing $7 billion annually to the local economy and $8 billion statewide. For more on UCI, visitwww.uci.edu.

Read the original post:
Nancy and Geoffrey Stack Family Foundation give $2 million to UCI Health - UCI News

Jersey City, New Jersey, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Verified Market Research recently published a report, Cell Isolation Market By Product (Consumables and Instruments), By Cell-Type (Human Cells and Animal Cells), By End-User (Hospitals and Diagnostic Laboratories), and By Geography.

The Cell Isolation Market size was valued at USD 6.39 Billion in 2020 and is projected to reach USD 20.50 Billion by 2028, growing at a CAGR of 15.70% from 2021 to 2028, according to the most recent study from Verified Market Research.

Download PDF Brochure: https://www.verifiedmarketresearch.com/download-sample/?rid=16724

Browse in-depth TOC on Cell Isolation Market

202 - Pages

126 Tables

37 Figures

Report Scope

Global Cell Isolation Market Overview

Cell separation also referred to as cell sorting or cell isolation, is the process of removing cells from biological samples such as tissue or blood. Cell separation is a powerful technology that assists in biological research. Rising incidences of chronic illnesses worldwide are likely to spice up the event of regenerative medicines or tissue engineering, which further boosts researchers' adoption of cell separation technologies.

The cell isolation market is driven by increasing government funding in cell-based research, the growing prevalence of cancer, and rising somatic cell research. Moreover, technological advancements, and increasing application of cell isolation for regenerative medicines are likely to spice up market growth during the forecast period.

Expansion of the worldwide cell separation technology market is attributed to a rise in technological advancements and a surge in investments in research & development, such as somatic cell research and cancer research. The rising geriatric population is another factor boosting the necessity for cell separation technologies, Moreover, the geriatric population, globally, is more susceptible to long-term neurological and other chronic illnesses, which, in turn, is driving research to develop a treatment for chronic illnesses. Furthermore, an increase in awareness about innovative technologies, such as microfluidics, fluorescent-activated cell sorting, and magnetically activated cell sorting is expected to propel the global cell separation technology market.

Key Developments

Key Players

The Global Cell Isolation Market study report will provide valuable insight emphasizing the global market. The major players in the market are

Based on the research, Verified Market Research has segmented the global Cell Isolation Market into Product, Cell-Type, End-User, and Geography.

Browse Related Reports:

Automated Cell Cultures Market By Product (Consumables, Reagents, Sera), By Application (Biopharmaceuticals, Drug Development), By End-User (Pharmaceuticals And Biotechnology Companies, Cell Banks), By Geography, And Forecast

Cell Harvesting Market By Application (Stem Cell Research, Biopharmaceuticals), By End-User (Academic Research Institutes, Biotechnology, and Biopharmaceutical Companies), By Geography, And Forecast

Stem Cell Manufacturing Market By Product (Consumables, Instruments), By Application (Research Applications, Clinical Applications), By Geography, And Forecast

Cell Biology Test Kits Market By Product (Bacteria Test Kits, Protein Test Kits), By Application (Pharmaceutical, Research Institutes, Biotech Laboratories) By Geography, And Forecast

Top 5 Cell Isolation-Cell Separation Companies Healthcare under a global lens

Visualize Cell Isolation Market using Verified Market Intelligence -:

Verified Market Intelligence is our BI Enabled Platform for narrative storytelling in this market. VMI offers in-depth forecasted trends and accurate Insights on over 20,000+ emerging & niche markets, helping you make critical revenue-impacting decisions for a brilliant future.

VMI provides a holistic overview and global competitive landscape with respect to Region, Country, Segment, and Key players of your market. Present your Market Report & findings with an inbuilt presentation feature saving over 70% of your time and resources for Investor, Sales & Marketing, R&D, and Product Development pitches. VMI enables data delivery In Excel and Interactive PDF formats with over 15+ Key Market Indicators for your market.

About Us

Verified Market Research is a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information-enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals, and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance and use industrial techniques to collect and analyze data on more than 15,000 high-impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.

We study 14+ categories from Semiconductor & Electronics, Chemicals, Advanced Materials, Aerospace & Defense, Energy & Power, Healthcare, Pharmaceuticals, Automotive & Transportation, Information & Communication Technology, Software & Services, Information Security, Mining, Minerals & Metals, Building & Construction, Agriculture industry and Medical Devices from over 100 countries.

Originally posted here:
Cell Isolation Market is expected to generate a revenue of USD 20.50 Billion by 2028, Globally, at 15.70% CAGR: Verified Market Research -...

A breed of pigs called Wisconsin Miniature Swine created by a team of UWMadison scientists will help researchers better model and understand human diseases. Photo: Jeff Miller

Cells from miniature pigs are paving the way for improved stem cell therapies.

A team led by University of WisconsinMadison Stem Cell & Regenerative Medicine Center researcher Wan-Ju Li offers an improved way to create a particularly valuable type of stem cell in pigs a cell that could speed the way to treatments that restore damaged tissues for conditions from osteoarthritis to heart disease in human patients.

In a study published in Scientific Reports, Lis team also provides insights into the reprogramming process that turns cells from one part of the body into pluripotent stem cells, a type of building block cell that can transform into any type of tissue. These new insights will help researchers study treatments for a wide range of diseases.

The researchers turned to pigs, a well-established animal model for potential human treatments, because translating research to improve human health is deeply important to Li, a professor of Orthopedics and Rehabilitation and Biomedical Engineering. He has spent much of his career studying cartilage and bone regeneration to develop innovative therapies to help people.

Li and members of his Musculoskeletal Biology and Regenerative Medicine Laboratory obtained skin cells from the ears of three different breeds of miniature pigs Wisconsin miniature swine, Yucatan miniature swine and Gttingen minipigs.

University of WisconsinMadison Stem Cell & Regenerative Medicine Center researcher Wan-Ju Li (left) shows a collagen fiber sample to Gwen Plunkett and Karen Plunkett. Funding from the Plunkett Family Foundation has contributed to research on cartilage repair therapies in UWMadisons Musculoskeletal Research Program.

The researchers reprogrammed the cells to create induced pluripotent stem cells and demonstrated that they have the capacity to become different types of tissue cells. Pluripotent stem cells are the bodys master cells, and they are invaluable to medicine since they can be used for the regeneration or repair of damaged tissues.

Findings of this study suggest that the miniature pig is a promising animal model for pre-clinical research. The team plans to use the established pig model to reproduce their recent findings of cartilage regeneration in rats as reported in Science Advances. Regenerating cartilage in animals even more alike to humans moves science one step closer to helping patients experiencing joint diseases such as osteoarthritis.

In successfully developing induced pluripotent stem cells from three different breeds of minipigs, we learned we can take somatic skin cells from these pigs that we programmed ourselves and then inject them back into the same animal to repair cartilage defects, says Li. Or we can create induced pluripotent stem cells from the skin cell that carried the gene causing cartilage diseases such as chondrodysplasia and put that into the culture dish and use that as a disease model to study disease formation.

Li says the approach can be applied to regenerative therapies targeting any organ or tissue.

The team also found that a particular protein complex involved in managing the way genes are expressed, and tied to cellular growth and survival, could influence how efficiently induced pluripotent stem cells are generated. While we successfully created induced pluripotent stem cells from the three different strains of pig, we noticed that some pigs had a higher reprogramming efficiency, says Li. So, the second part of our findings, which is significant in biology, is understanding how these differences occur and why.

These findings, he says, may directly translate to understanding differences in the effectiveness of induced pluripotent stem cell generation between individual people one study has shown cellular reprogramming efficiency varying by age and ancestry and lead to better tailored therapies.

I want to make sure that our findings in stem cell research can be used to help people, says Li. I just feel this internal drive to study this area and I feel good knowing this model carries significant weight in terms of its potential for translational stem cell research and the development of therapeutic treatments.

Interest in moving these treatments forward has grown, and while the study was funded in part by the National Institutes of Health, Li also received support from the Milwaukee-based Plunkett Family Foundation through their donation to the UW Stem Cell & Regenerative Medicine Center. After hearing of Lis research, Gwen Plunkett and her daughter Karen visited Lis lab in 2019 to learn more. They were inspired to support research into stem cells for cartilage regeneration.

Innovation in medicine sparks critical change, for the world and the survival of our species, and the Plunkett Family mission is to be a catalyst in stem cell and regenerative medicine research, says Karen Plunkett.

The donation was profoundly impactful, says Li, allowed him to further his goal of using stem cells to help patients living with osteoarthritis and other joint diseases many of whom write his lab regularly in hope of finding a clinical trial opportunity.

I have to keep saying, Wait for another two, three years, maybe well be ready for a clinical trial, Li says. But for me, its time to move on and really do our larger animal studies to fulfill our promise. At least that way, I can fill the gap between the lab and clinical trials as the larger animals must be studied before you go into a clinical trial.

This research was supported by grants from the National Institutes of Health (R01 AR064803), the Plunkett Family Foundation and UW Carbon Cancer Center.

Originally posted here:
Creating stem cells from minipigs offers promise for improved treatments - University of Wisconsin-Madison

Calgary, Alberta--(Newsfile Corp. - September 14, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) ("Hemostemix" or the "Company") is pleased to announce the appointment of Dr. Renzo Cecere, MD, FRCSC, to its Scientific Advisory Board.

Dr. Cecere is the McGill University Chief of Cardiac Surgery, Surgical Director of the Heart Failure and Heart Transplantation Program, and Director of the Mechanical Circulatory Support Program. He is also Associate Member of the McGill University Department of Mechanical Engineering, and a Director and Principal Investigator of the Research Institute of the MUHC Myocardial Regeneration Laboratory.

For over a decade, Dr. Cecere's lab has been investigating novel methods to strengthen the stem-cell induced regeneration of infarcted heart tissue. Dr. Cecere has utilized placenta-derived stem cells and investigated their regenerative potential in different animal models of myocardial infarction ("MI"). More recently, Dr. Cecere's lab is actively involved in a project to create a platform to generate patient-specific cardiomyocytes from the blood of patients with heart failure. In Dr. Cecere's recent project (under review, Journal of Tissue Engineering and Regenerative Medicine), the team encapsulated placenta derived stem cells in a hydrogel scaffold and implanted it in a rat MI model. The stem cell/scaffold composite enhanced several parameters of cardiac function, including ejection fraction and fractional shortening, while also reducing fibrosis and increasing angiogenesis. In fact, Dr. Cecere's lab recently published a systematic review and meta-analysis that demonstrated that stem cells combined with bioactive scaffolds provide enhanced tissue regeneration in animal models of MI, compared to stem cells injected alone. This study paves the way for future research and clinical trials, supporting the use of ACP-01-based bioactive scaffolds to improve the stem cell-induced repair after a MI.

"I have worked in the field of heart-based stem cell science for more than a decade, and I find ACP-01's unique properties, safety profile and statistically significant preliminary intramyocardial efficacy results to be very promising" said Dr. Cecere. I look forward to collaborating with management to create the best product to repair hearts before an infarct or following an infarct, and designing a clinical trial of ACP-01 that proves its efficacy" said Dr. Cecere.

"Hemostemix is delighted to welcome Dr. Cecere to our team. His appointment to the SAB is the first of many areas of collaboration. As one of Canada's most well-regarded stem cell focused heart transplant surgeons, Dr. Cecere and his team enable Hemostemix to fast-track product development and clinical trials. We very much look forward to his counsel and his teams' collaboration to trial ACP-01 based bioactive scaffolds to improve stem cell-induced repair of the heart," stated Thomas Smeenk, CEO.

ABOUT HEMOSTEMIX

Hemostemix is an autologous stem cell therapy company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company has developed, patented, and is scaling a patient's blood-based stem cell therapeutics platform that includes angiogenic cell precursors, neuronal cell precursor and cardiomyocyte cell precursors. Seven studies including 260 ACP-01 recipients define its safety and efficacy profile as a treatment for heart diseases such as Dilated and Ischemic Cardiomyopathy, Angina, and diseases of Ischemia such as Critical Limb Ischemia. The Company owns 91 patents across five patent families. For more information, please visit http://www.hemostemix.com.

For further information, please contact: Thomas Smeenk, President, CEO & Co-FounderEM: tsmeenk@hemostemix.com PH: 905-580-4170

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein are forward-looking information. In particular, this news release contains forward-looking information in relation to: the lead product ACP-01, future studies of ACP-01 in bioactive scaffolds to improve the stem cell-induced repair after an infarct, the company's Clinical Trial results, and the results of the retrospective study of ischemic and dilated cardiomyopathy, and the commercialization of ACP-01. There can be no assurance that such forward-looking information will prove to be accurate. Actual results and future events could differ materially from those anticipated in such forward-looking information. This forward-looking information reflects Hemostemix's current beliefs and is based on information currently available to Hemostemix and on assumptions Hemostemix believes are reasonable. These assumptions include, but are not limited to: the underlying value of Hemostemix and its Common Shares; the successful resolution of the litigation that Hemostemix is pursuing or defending (the "Litigation"); the results of ACP-01 research, trials, studies and analyses, including the analysis being equivalent to or better than previous research, trials or studies; the receipt of all required regulatory approvals for research, trials or studies; the level of activity, market acceptance and market trends in the healthcare sector; the economy generally; consumer interest in Hemostemix's services and products; competition and Hemostemix's competitive advantages; and Hemostemix obtaining satisfactory financing to fund Hemostemix's operations including any research, trials or studies, and any Litigation. Forward-looking information is Subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Hemostemix to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: the ability of Hemostemix to complete clinical trials, complete a satisfactory analyses and file the results of such analyses to gain regulatory approval of a phase II or phase III clinical trial of ACP-01; potential litigation Hemostemis mayface; general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; delay or failure to receive board or regulatory approvals; the actual results of future operations including the actual results of future research, trials or studies; competition; changes in legislation affecting Hemostemix; the timing and availability of external financing on acceptable terms; long-term capital requirements and future developments in Hemostemix's markets and the markets in which it expects to compete; lack of qualified, skilled labour or loss of key individuals; and risks related to the COVID-19 pandemic including various recommendations, orders and measures of governmental authorities to try to limit the pandemic, including travel restrictions, border closures, non-essential business closures service disruptions, quarantines, self-isolations, shelters-in-place and social distancing, disruptions to markets, disruptions to economic activity and financings, disruptions to supply chains and sales channels, and a deterioration of general economic conditions including a possible national or global recession or depression;the potential impact that the COVID-19 pandemic may have on Hemostemix which may include a decreased demand for the services that Hemostemix offers; and a deterioration of financial markets that could limit Hemostemix's ability to obtain external financing. A description of additional risk factors that may cause actual results to differ materially from forward-looking information can be found in Hemostemix's disclosure documents on the SEDAR website at http://www.sedar.com. Although Hemostemix has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Forward-looking information contained in this news release is expressly qualified by this cautionary statement. The forward-looking information contained in this news release represents the expectations of Hemostemix as of the date of this news release and, accordingly, it is Subject to change after such date. However, Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/137137

View original post here:
Hemostemix Announces the Appointment of Dr. Renzo Cecere, MD, FRCSC to Its Scientific Advisory Board - Yahoo Finance

September 15, 2022 The intestine is very susceptible and is affected by the harsh conditions caused by DNA-altering agents, such asradiationand chemotherapy, during cancer treatment. For example, many patients with tumors in the gastrointestinal cavity receive radiotherapy, a treatment that often also damages the healthy intestine and affects its regenerative capacity. It is therefore very important to understand how intestinal epithelial regeneration occurs. The cellular and molecular mechanisms involved in this key process are not yet fully understood.

Researchers at theSpanish National Cancer Research Centre(CNIO) have now discovered one of the cellular and molecular mechanisms essential for the regeneration of the intestinal epithelium. This finding lays the foundations for stimulating this process if it fails, and for protecting it againstdamage caused by radiotherapyand chemotherapy.

According to the study, what prompts intestinal stem cells to regenerate the mucosa depends on the communication between different cell types in the epithelial tissue. The researchers have also found a way to intervene in this communication, and thereby, boost intestinal regeneration.

The paperis published this week inJournal of Experimental Medicine. The research is led by the head of the CNIO's Growth Factors, Nutrients and Cancer Group, Nabil Djouder, and Almudena Chaves-Prez and Karla Santos-de-Frutos are first authors.

The group has spent years researching how to improve the regeneration of various organsparticularly the liver and intestinal mucosaand thus mitigate the effects of radiotherapy. Their findings during this period have been published in high-impact journals.

"Regeneration of the intestinal epithelium is very important in the proper functioning of the intestine," explains Djouder. "Until now, we knew that it was driven by powerful mitogenic factorsproteinsthat stimulate the proliferation of intestinal stem cells, but we didn't know how these factors were regulated."

This new study suggests thatunexpectedly for the researchers it is the progenitor cells involved in regenerating the epithelial mucosa that modulate the production of mitogenic factors. The process is as follows: when severe damage occurs, injury to the progenitor cells leads to tissue inflammation; this in turn slows down the production of mitogenic factors and thus the proliferation of stem cells and the subsequent regeneration of the mucous membrane.

"For us, this communication between at least four different cell types is new: progenitor cells, which differentiate to form the epithelial mucosa; cells that secrete mitogenic factors; inflammatory cells; and intestinal stem cells themselves," says Djouder. "This communication must be very well controlled, so that the tissue responds appropriately to aggressions."

"That progenitor cells communicate with inflammatory cells and coordinate the proliferation rate of intestinal stem cells is fascinating," he adds.

Djouder places particular emphasis on the new role that progenitor cells have been found to play: "Our study suggests that progenitor cells are not mere bystanders in the process of epithelial regeneration, but play an active and important role in the decisions that intestinal stem cells make in regeneration. Progenitor cells tell intestinal stem cells when and how to divide, and thus control their self-regeneration."

"This study has allowed us to better understand cell cooperation in order to find new ways to reduce adverse effects in traditional cancer treatments," say Chaves-Prez and Santos-de-Frutos, lead authors of the paper.

The group has also confirmed findings observed in previous work, namely that c-MYC oncogene plays a key role in regeneration. Due to radiation damage and the increase of c-MYC in progenitor cells, inflammation in the intestine increases and mitogenic protein levels are reduced; however, by removing or inhibiting c-MYC, the process is reversed: inflammation is reduced, mitogenic factors increase and intestinal regeneration during severe damage improves.

"Our data show an unexpected role for progenitor cells in the control of inflammatory signalling and mitogenic factor production, essential for maintaining intestinal stem cell proliferation and tissue regeneration," the authors write.

The finding, they say, breaks new ground in research into how to counteract the side effects of radiotherapy in patients with gastrointestinal cancer.

The work has been funded by the Ministry of Science and Innovation, the Carlos III Health Institute, the European Regional Development Fund, the Community of Madrid and the Spanish Association Against Cancer.

For more information:https://www.cnio.es/en/

Read the original here:
Discovered Key Mechanisms to Improve Intestinal Regeneration and Alleviate the Side Effects of Radiotherapy - Imaging Technology News

News Release

Wednesday, September 14, 2022

NIH study shows the role of transcription factors in facilitating cell regeneration.

National Institutes of Health researchers have discovered a specific network of proteins that is necessary to restore hearing in zebrafish through cell regeneration. The study, led by investigators at the National Human Genome Research Institute (NHGRI), may inform the development of treatments for hearing loss in humans. The findings were published in Cell Genomics.

Although hair cell loss cannot be replaced in humans, many animals, including zebrafish, can restore hearing after injury through the regeneration of hair cells. The regenerative properties of zebrafish hair cells prompted researchers to use this animal to understand some fundamental properties of regeneration.

Hearing loss affects around 37.5 million Americans, and most cases come from the loss of hearing receptors known as hair cells in the inner ear. Bristles that stick out of these microscopic hair cells move and bend when sound travels into our ears, resulting in electric signals sent through nerves and into our brains that allow us to process sound.

Humans and zebrafish are visually quite different, but at a genomic level, they share more than 70% of their genes. This genomic similarity offers the potential for researchers to understand the biology of cell regeneration in zebrafish before translating the findings to humans.

Erin Jimenez, Ph.D., a postdoctoral fellow in the laboratory of Shawn Burgess, Ph.D., senior investigator in the National Human Genome Research Institutes (NHGRI) Translational and Functional Genomics Branch, led the study in collaboration with researchers Ivan Ovcharenko, Ph.D., and Wei Song, Ph.D., at the National Library of Medicines National Center for Biotechnology Information.

Humans and other mammals are born with a set number of hair cells that are slowly lost through aging and trauma. However some animals, such as zebrafish, can regenerate hair cells and recover hearing after injury, said Burgess. How and why regeneration happens in these animals remain a mystery that many scientists would like to unravel.

Using a combination of genomic techniques and computational-based machine learning, Jimenez and her collaborators found that hair cell regeneration in zebrafish relied on a network of proteins that can switch genes on and off, known as transcription factors. To properly identify which transcription factors were at play, the researchers first had to look at the enhancer sequences within the zebrafish genome.

If transcription factors are thought of as the keys that turn a car on and off, enhancer sequences are the cars ignition switch. Both parts need to interact to make a car run, just like how transcription factors need to bind to specific enhancer sequences to express a gene.

The researchers used new genomic techniques called single-cell RNA sequencing and single-cell assay for transposase-accessible chromatin using sequencing to identify the enhancer sequences and their corresponding transcription factors that play a role in hair cell regeneration.

Our study identified two families of transcription factors that work together to activate hair cell regeneration in zebrafish, called Sox and Six transcription factors, said Jimenez.

First, the Sox transcription factors initiate the regeneration response in surrounding cells, called support cells. Next, the Sox and Six transcription factors cooperate to turn those support cells into hair cells.

When hair cells die in zebrafish, nearby support cells start replicating. These support cells are like stem cells because of their ability to become other cell types. Researchers had identified some of the factors that convert support cells into hair cells, but what was not understood is how and where the genes encoding those factors turn on and are coordinated with other unknown factors.

We have identified a unique combination of transcription factors that trigger regeneration in zebrafish. Further down the line, this group of zebrafish transcription factors might become a biological target that may lead to the development of novel therapy to treat hearing loss in humans, Jimenez said.

The National Human Genome Research Institute (NHGRI) is one of the 27 institutes and centers at the NIH, an agency of the Department of Health and Human Services. The NHGRI Division of Intramural Research develops and implements technology to understand, diagnose and treat genomic and genetic diseases. Additional information about NHGRI can be found at: https://www.genome.gov.

About the National Institutes of Health (NIH):NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov.

NIHTurning Discovery Into Health

Erin Jimenez, Claire C. Slevin, Wei Song, Zelin Chen, Stephen C. Frederickson, Derek Gildea, Weiwei Wu, Abdel G. Elkahloun, Ivan Ovcharenko, Shawn M. Burgess.A regulatory network of Sox and Six transcription factors initiate a cell fate transformation during hearing regeneration in adult zebrafish. Cell Genomics, 2022.https://doi.org/10.1016/j.xgen.2022.100170.

###

Read more here:
Genomics study identifies unique set of proteins that restores hearing in zebrafish - National Institutes of Health (.gov)